

Rights issue SEK 30m gross proceeds

On 1 July, the company announced the results of its rights issue. Gross proceeds amount to ca. SEK 30m, allowing the company to commence phase I of its breast cancer vaccine candidate ES2B-C001 in 2025e while maintaining cash reach to early 2026e. Exercise of linked warrants in late 2024e and the fall of 2025e could result in substantial additional inflows. We reiterate Buy and slightly reduce our price target to SEK 8, from SEK 9, as a higher assumed success probability for ES2B-C001 does not fully offset the current and potential future dilution from the rights issue and linked warrants.

Cash inflows and operational implications

The rights issue was subscribed by 50.1% in total, roughly equivalent to the guaranteed amount, resulting in immediate gross proceeds of SEK 30m. Management had previously indicated that this would be sufficient to commence phase I work on ES2B-C001 next year; however, pending finalization of the trial design and related costs, it cautions that subscription of the full amount, which would have resulted in gross proceeds of SEK 60m, might have been required to complete phase I. We note two recent high-profile publications (phase Ib malaria vaccine candidate data in The Lancet, ESACT poster on the use of the cell line).

Financial forecasts

At the end of Q1 '24, the cash position stood at SEK 60m; inflows since then include a SEK 22.5m dividend from the associate AdaptVac and estimated net proceeds of SEK 27.5m from the rights issue. Management estimates cash reach to early 2026, based on the premise that the full proceeds from the rights issue will be invested in clinical work on ES2B-C001. The number of shares has increased to 83,626,630 from 51,404,958 as a result of the rights issue. If all linked warrants from the TO10 and TO11 series were exercised in late '24 and the fall of '25, respectively, this would bring the total number of shares to 148,069,974. The exercise price is linked to the volume-weighted average share price; at a price of SEK 1, additional cash inflows of ca. SEK 60m look possible, which we have prudently excluded from our forecasts as they would likely be reinvested.

Investment thesis: operational progress to largely compensate for dilution

Initial dilution from the rights issue amounts to ca. 40%; in the event of exercise of all linked warrants, total dilution would rise to >70%. Mitigating effects include the resulting cash proceeds and an increase in the success probability of ES2B-C001 with financing for the phase I start now available. ES2B-C001 now accounts for 72% of our fair value estimate of SEK 8 per share. Risks: clinical, regulatory and commercial risks, warrant exercise prices and dependence on future financing.

SEKm	2022	2023	2024e	2025e	2026e
Revenues	6	9	8	8	8
EBITDA	(126)	(104)	(50)	(40)	(40)
EBIT	(128)	(101)	(27)	(39)	(39)
EPS	(3,42)	(2,11)	(0,38)	(0,56)	(0,57)
EPS adj	(3,42)	(2,11)	(0,38)	(0,56)	(0,57)
DPS	-	-	-	-	-
EV/EBITDA	-	-	-	-	-
EV/EBIT	-	-	-	-	-
P/E adj	-	-	-	-	-
P/B	4,78	1,42	1,39	3,19	4,53
ROE (%)	-	-	-	-	-
Div yield (%)	-	-	-	-	-
Net debt	(109)	(57)	(55)	(14)	(3)

Source: Pareto Securities

Target price (SEK)	8,0	▲	BUY
Share price (SEK)	1,1	-	HOLD
		▼	SELL


Forecast changes

%	2024e	2025e	2026e
Revenues	(6)	(6)	NM
EBITDA	-	-	NM
EBIT adj	-	-	NM
EPS reported	61	28	NM
EPS adj	61	28	NM

Source: Pareto Securities

Ticker	EXPRS2.ST, EXPRS2 SS
Sector	Healthcare
Shares fully diluted (m)	83,6
Market cap (SEKm)	93
Net debt (SEKm)	-55
Minority interests (SEKm)	0
Enterprise value 24e (SEKm)	38
Free float (%)	83

Performance



Source: FactSet

Pareto Securities AS has been paid by the issuer to produce this research report. This material is considered by Pareto Securities to qualify as an acceptable minor non-monetary benefit according to the EU MIFID 2 directive.

Analysts

Marietta Miemietz
+49 69 58997 434, marietta.miemietz@paretosec.com

Valuation: SOTP-based FV of SEK 8/share

Our conservative assumptions include late-line use only of the cancer vaccine ES2B-C001

Our NPV-based sum-of-the-parts model shown below suggests a fair value of SEK 1,158m, or SEK 8 per share on a fully diluted basis, based on arguably conservative assumptions. As previously noted, our base case assumption for the cancer vaccine ES2B-C001, which accounts for 72% of our fair value estimate, is that it will be relegated to the salvage setting, with significant upside in case of positive data in lucrative earlier settings. We expect the project to be phase I-ready next year, pending standard prerequisites for enrolment, notably approval of a clinical trial application and selection of a contract research organization. With financing to commence phase I now available, we assume the standard success probability of 11.4% for phase I cancer assets in their lead indication. Previously, we had regarded ES2B-C001 as a preclinical asset, with an estimated success probability of less than 4%.

We prudently do not attribute any value to ExpreS2ion Biotech's 34% stake in AdaptVac. Moreover, we have refrained from attributing a value to the focus pipeline, pending substantive pre-clinical data. Our fully diluted number of shares estimate assumes the exercise of all linked warrants; consequently, we have included ca. SEK 60m in proceeds based on the assumption of a SEK 1 exercise price in our estimated cash position. The latter has been derived from end of Q1 2024 cash position of SEK 60m, the receipt of a SEK 22.5m dividend from AdaptVac in Q2, and estimated net proceeds from the rights issue of SEK 27.5m, less estimated cash use of SEK 15m since the end of Q1. In the absence of visibility on timelines to profitability, we do not include tax-loss carry-forwards as an asset in our valuation on a standalone basis but note that this could be a consideration in a hypothetical bid scenario. We have applied a 10% discount rate.

Pipeline newsflow provides value inflection points

Upside notably arises from the de-risking of pipeline assets, from the potential use of ES2B-C001 in earlier lines of cancer treatment, from the focus pipeline, and from any potential value of AdaptVac's underlying business. Downside risks arise primarily from funding constraints and the potential failure of assets in development. Key expected newsflow over the next twelve to 18 months includes the entry of ES2B-C001 into the clinic in breast cancer, phase IIb data in malaria and announcements of lead candidates from the exploratory pipeline.

Sum of the Parts Valuation	NPV (SEK m)	Per Share (SEK)	% of Total Fair Value
ES2B-C001	849	5.73	72 %
Malaria	92	0.62	8 %
Influenza	62	0.42	5 %
Total	1 003	6.77	85 %
Net cash (debt)	155	1.05	13 %
Shares outstanding (Pro Forma for Dilution)	148,070		
Fair Value	1 158	8.00	100 %

Source: Pareto research

PROFIT & LOSS (fiscal year) (SEKm)	2019	2020	2021	2022	2023	2024e	2025e	2026e
Revenues	14	15	14	6	9	8	8	8
EBITDA	(16)	(28)	(47)	(126)	(104)	(50)	(40)	(40)
Depreciation & amortisation	(3)	(3)	(2)	(1)	(2)	-	-	-
EBIT	(19)	(31)	(48)	(128)	(101)	(27)	(39)	(39)
Net interest	(1)	(4)	1	-	(5)	1	1	0
Other financial items	-	-	-	-	-	-	-	-
Profit before taxes	(20)	(35)	(48)	(128)	(106)	(26)	(38)	(39)
Taxes	2	3	4	8	9	-	-	-
Minority interest	-	-	-	-	-	-	-	-
Net profit	(17)	(32)	(44)	(120)	(97)	(26)	(38)	(39)
EPS reported	(0,63)	(1,15)	(1,59)	(3,42)	(2,11)	(0,38)	(0,56)	(0,57)
EPS adjusted	(0,63)	(1,15)	(1,59)	(3,42)	(2,11)	(0,38)	(0,56)	(0,57)
DPS	-	-	-	-	-	-	-	-
BALANCE SHEET (SEKm)	2019	2020	2021	2022	2023	2024e	2025e	2026e
Tangible non current assets	1	1	1	1	2	3	4	6
Other non-current assets	7	5	105	5	8	10	12	14
Other current assets	5	6	9	21	11	10	10	10
Cash & equivalents	5	107	37	111	58	55	14	3
Total assets	19	119	152	137	79	78	41	32
Total equity	(1)	95	140	103	65	67	29	20
Interest-bearing non-current debt	1	2	2	2	0	0	0	0
Interest-bearing current debt	-	-	-	-	-	-	-	-
Other Debt	18	22	10	32	13	11	11	11
Total liabilities & equity	19	119	152	137	79	78	41	32
CASH FLOW (SEKm)	2019	2020	2021	2022	2023	2024e	2025e	2026e
Cash earnings	(12)	(17)	(47)	(88)	(111)	(28)	(38)	(39)
Change in working capital	(1)	(2)	1	(11)	10	1	-	-
Cash flow from investments	(1)	(1)	1	0	2	(3)	(3)	(3)
Cash flow from financing	13	123	75	61	48	28	-	30
Net cash flow	(1)	101	(70)	74	(53)	(2)	(41)	(12)
VALUATION (SEKm)	2019	2020	2021	2022	2023	2024e	2025e	2026e
Share price (SEK end)	2,78	8,4	28,5	13,1	1,80	1,11	1,11	1,11
Number of shares end period	28	28	28	38	51	84	84	84
Net interest bearing debt	(4)	(104)	(35)	(109)	(57)	(55)	(14)	(3)
Enterprise value	73	129	751	385	35	38	79	90
EV/Sales	5,3	8,4	-	-	4,0	4,7	9,8	11,3
EV/EBITDA	-	-	-	-	-	-	-	-
EV/EBIT	-	-	-	-	-	-	-	-
P/E reported	-	-	-	-	-	-	-	-
P/E adjusted	-	-	-	-	-	-	-	-
P/B	-	2,5	5,6	4,8	1,4	1,4	3,2	4,5
FINANCIAL ANALYSIS	2019	2020	2021	2022	2023	2024e	2025e	2026e
ROE adjusted (%)	-	-	-	-	-	-	-	-
Dividend yield (%)	-	-	-	-	-	-	-	-
EBITDA margin (%)	-	-	-	-	-	-	-	-
EBIT margin (%)	-	-	-	-	-	-	-	-
NIBD/EBITDA	0,25	3,69	0,76	0,86	0,55	1,10	0,35	0,06
EBITDA/Net interest	-	-	52,94	-	-	50,69	42,23	-

Disclaimer and legal disclosures

Origin of the publication or report

This publication or report originates from Pareto Securities AS, reg. no. 956 632 374 (Norway), Pareto Securities AS, Frankfurt branch, reg. no. DE 320 965 513 / HR B 109177 (Germany) or Pareto Securities AB, reg. no. 556206-8956 (Sweden) (together the Group Companies or the "Pareto Securities Group") acting through their common unit Pareto Securities Research. The Group Companies are supervised by the Financial Supervisory Authority of their respective home countries.

Content of the publication or report

This publication or report has been prepared solely by Pareto Securities Research.

Opinions or suggestions from Pareto Securities Research may deviate from recommendations or opinions presented by other departments or companies in the Pareto Securities Group. The reason may typically be the result of differing time horizons, methodologies, contexts or other factors.

Sponsored research

Please note that if this report is labelled as "sponsored research" on the front page, Pareto Securities has entered into an agreement with the company about the preparation of research reports and receives compensation from the company for this service. Sponsored research is prepared by the Research Department of Pareto Securities without any instruction rights by the company. Sponsored research is however commissioned for and paid by the company and such material is considered by Pareto Securities to qualify as an acceptable minor non-monetary benefit according to the EU MiFID II Directive.

Basis and methods for assessment

Opinions and price targets are based on one or more methods of valuation, for instance cash flow analysis, use of multiples, behavioral technical analyses of underlying market movements in combination with considerations of the market situation and the time horizon. Key assumptions of forecasts, price targets and projections in research cited or reproduced appear in the research material from the named sources. The date of publication appears from the research material cited or reproduced. Opinions and estimates may be updated in subsequent versions of the publication or report, provided that the relevant company/issuer is treated anew in such later versions of the publication or report.

Pareto Securities Research may provide credit research with more specific price targets based on different valuation methods, including the analysis of key credit ratios and other factors describing the securities creditworthiness, peer group analysis of securities with similar creditworthiness and different DCF-valuations. All descriptions of loan agreement structures and loan agreement features are obtained from sources which Pareto Securities Research believes to be reliable, but Pareto Securities Research does not represent or warrant their accuracy. Be aware that investors should go through the specific complete loan agreement before investing in any bonds and not base an investment decision based solely on information contained in this publication or report.

Pareto Securities Research has no fixed schedule for updating publications or reports.

Unless otherwise stated on the first page, the publication or report has not been reviewed by the issuer before dissemination. In instances where all or part of a report is presented to the issuer prior to publication, the purpose is to ensure that facts are correct.

Validity of the publication or report

All opinions and estimates in this publication or report are, regardless of source, given in good faith and may only be valid as of the stated date of this publication or report and are subject to change without notice.

No individual investment or tax advice

The publication or report is intended only to provide general and preliminary information to investors and shall not be construed as the basis for any investment decision. This publication or report has been prepared by Pareto Securities Research as general information for private use of investors to whom the publication or report has been distributed, but it is not intended as a personal recommendation of particular financial instruments or strategies and thus it does not provide individually tailored investment advice, and does not take into account the individual investor's particular financial situation, existing holdings or liabilities, investment knowledge and experience, investment objective and horizon or risk profile and preferences. The investor must particularly ensure the suitability of an investment as regards his/her financial and fiscal situation and investment objectives. The investor bears the risk of losses in connection with an investment.

Before acting on any information in this publication or report, we recommend consulting your financial advisor.

The information contained in this publication or report does not constitute advice on the tax consequences of making any particular investment decision. Each investor shall make his/her own appraisal of the tax and other financial merits of his/her investment.

Sources

This publication or report may be based on or contain information, such as opinions, recommendations, estimates, price targets and valuations which emanate from Pareto Securities Research' analysts or representatives, publicly available information, information from other units or companies in the Group Companies, or other named sources.

To the extent this publication or report is based on or contains information emanating from other sources ("Other Sources") than Pareto Securities Research ("External Information"), Pareto Securities Research has deemed the Other Sources to be reliable but neither the companies in the Pareto Securities Group, others associated or affiliated with said companies nor any other person, guarantee the accuracy, adequacy or completeness of the External Information.

Sustainability reports

In accordance with disclosure requirements pursuant to the Norwegian Securities Dealers Association Industry Standard no. 3, link to the company's sustainability reports or similar can be found at https://paretosec.com/compliancedownloads/Sustainability_reports.pdf.

Ratings

Equity ratings:

"Buy"	Pareto Securities Research expects this financial instrument's total return to exceed 10% over the next 12 months
"Hold"	Pareto Securities Research expects this financial instrument's total return to be between -10% and 10% over the next 12 months
"Sell"	Pareto Securities Research expects this financial instrument's total return to be negative by more than 10% over the next 12 months
"Not Rated"	A recommendation, target price, and/or financial forecast have not been disclosed. This may be due to legal, regulatory, or policy constraints, or where Pareto Securities Research lacks sufficient fundamental information to rate the financial instrument. The previous recommendation and, if applicable, the target price, are no longer valid and should not be relied upon.

Analysts Certification

The research analyst(s) whose name(s) appear on research reports prepared by Pareto Securities Research certify that: (i) all of the views expressed in the research report accurately reflect their personal views about the subject security or issuer, and (ii) no part of the research analysts' compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analysts in research reports that are prepared by Pareto Securities Research.

The research analysts whose names appears on research reports prepared by Pareto Securities Research received compensation that is based upon various factors including Pareto Securities' total revenues, a portion of which are generated by Pareto Securities' investment banking activities.

Limitation of liability

Pareto Securities Group or other associated and affiliated companies assume no liability as regards to any investment, divestment or retention decision taken by the investor on the basis of this publication or report. In no event will entities of the Pareto Securities Group or other associated and affiliated companies be liable for direct, indirect or incidental, special or consequential damages resulting from the information in this publication or report.

Neither the information nor any opinion which may be expressed herein constitutes a solicitation by Pareto Securities Research of purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. All information contained in this research report has been compiled from sources believed to be reliable. However, no representation or warranty, express or implied, is made with respect to the completeness or accuracy of its contents, and it is not to be relied upon as authoritative.

Risk information

The risk of investing in certain financial instruments, including those mentioned in this document, is generally high, as their market value is exposed to a lot of different factors such as the operational and financial conditions of the relevant company, growth prospects, change in interest rates, the economic and political environment, foreign exchange rates, shifts in market sentiments etc. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. Past performance is not a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. When investing in individual shares, the investor may lose all or part of the investments.

Conflicts of interest

Companies in the Pareto Securities Group, affiliates or staff of companies in the Pareto Securities Group, may perform services for, solicit business from, make a market in, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

In addition Pareto Securities Group, or affiliates, may from time to time have a broking, advisory or other relationship with a company which is the subject of or referred to in the relevant Research, including acting as that company's official or sponsoring broker and providing investment banking or other financial services. It is the policy of Pareto to seek to act as corporate adviser or broker to some of the companies which are covered by Pareto Securities Research. Accordingly companies covered in any Research may be the subject of marketing initiatives by the Investment Banking Department.

To limit possible conflicts of interest and counter the abuse of inside knowledge, the analysts of Pareto Securities Research are subject to internal rules on sound ethical conduct, the management of inside information, handling of unpublished research material, contact with other units of the Group Companies and personal account dealing. The internal rules have been prepared in accordance with applicable legislation and relevant industry standards. The object of the internal rules is for example to ensure that no analyst will abuse or cause others to abuse confidential information. It is the policy of Pareto Securities Research that no link exists between revenues from capital markets activities and individual analyst remuneration. The Group Companies are members of national securities dealers' associations in each of the countries in which the Group Companies have their head offices. Internal rules have been developed in accordance with recommendations issued by the securities dealers' associations. This material has been prepared following the Pareto Securities Conflict of Interest Policy.

The guidelines in the policy include rules and measures aimed at achieving a sufficient degree of independence between various departments, business areas and sub-business areas within the Pareto Securities Group in order to, as far as possible, avoid conflicts of interest from arising between such departments, business areas and sub-business areas as well as their customers. One purpose of such measures is to restrict the flow of information between certain business areas and sub-business areas within the Pareto Securities Group, where conflicts of interest may arise and to safeguard the impartialness of the employees. For example, the Investment Banking departments and certain other departments included in the Pareto Securities Group are surrounded by arrangements, so-called Chinese Walls, to restrict the flows of sensitive information from such departments. The internal guidelines also include, without limitation, rules aimed at securing the impartialness of, e.g., analysts working in the Pareto Securities Research departments, restrictions with regard to the remuneration paid to such analysts, requirements with respect to the independence of analysts from other departments within the Pareto Securities Group rules concerning contacts with covered companies and rules concerning personal account trading carried out by analysts.

Distribution restriction

The securities referred to in this publication or report may not be eligible for sale in some jurisdictions and persons into whose possession this document comes should inform themselves about and observe any such restrictions. This publication or report is not intended for and must not be distributed to private customers in the US, or retail clients in the United Kingdom, as defined by the Financial Conduct Authority (FCA).

This research is only intended for and may only be distributed to institutional investors in the United States and U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Pareto Securities Inc. at 150 East 52nd Street, New York, NY 10022, Tel. 212 829 4200.

Pareto Securities Inc. is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of FINRA & SIPC. U.S. To the extent required by applicable U.S. laws and regulations, Pareto Securities Inc. accepts responsibility for the contents of this publication. Investment products provided by or through Pareto Securities Inc. or Pareto Securities Research are not FDIC insured, may lose value and are not guaranteed by Pareto Securities Inc. or Pareto Securities Research. Investing in non-U.S. securities may entail certain risks. This document does not constitute or form part of any offer or sale or subscription, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements. The information available about non-U.S. companies may be limited, and non-U.S. companies are generally not subject to the same uniform auditing and reporting standards as U.S. companies. Market rules, conventions and practices may differ from U.S. markets, adding to transaction costs or causing delays in the purchase or sale of securities. Securities of some non-U.S. companies may not be as liquid as securities of comparable U.S. companies. Fluctuations in the values of national currencies, as well as the potential for governmental restrictions on currency movements, can significantly erode principal and investment returns. Pareto Securities Research may have material conflicts of interest related to the production or distribution of this research report which, with regard to Pareto Securities Research, are disclosed herein.

Distribution in Singapore

Pareto Securities Pte Ltd holds a Capital Markets Services License is an exempt financial advisor under Financial Advisers Act, Chapter 110 ("FAA") of Singapore and a subsidiary of Pareto Securities AS.

This report is directed solely to persons who qualify as "accredited investors", "expert investors" and "institutional investors" as defined in section 4A(1) Securities and Futures Act, Chapter 289 ("SFA") of Singapore. This report is intended for general circulation amongst such investors and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should seek advice from a financial adviser regarding the suitability of any product referred to in this report, taking into account your specific financial objectives, financial situation or particular needs before making a commitment to purchase any such product. Please contact Pareto Securities Pte Ltd, 16 Collyer Quay, # 27-02 Income at Raffles, Singapore 049318, at +65 6408 9800 in matters arising from, or in connection with this report.

Additional provisions on Recommendations distributed in the Canada

Canadian recipients of this research report are advised that this research report is not, and under no circumstances is it to be construed as an offer to sell or a solicitation of or an offer to buy any securities that may be described herein. This research report is not, and under no circumstances is it to be construed as, a prospectus, offering memorandum, advertisement or a public offering in Canada of such securities. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon this research report or the merits of any securities described or discussed herein and any representation to the contrary is an offence. Any securities described or discussed within this research report may only be distributed in Canada in accordance with applicable provincial and territorial securities laws. Any offer or sale in Canada of the securities described or discussed herein will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. Under no circumstances is the information contained herein to be construed as investment advice in any province or territory of Canada nor should it be construed as being tailored to the needs of the recipient. Canadian recipients are advised that Pareto Securities AS, its affiliates and its authorized agents are not responsible for, nor do they accept, any liability whatsoever for any direct or consequential loss arising from any use of this research report or the information contained herein.

Distribution in United Kingdom

This publication is issued for the benefit of persons who qualify as eligible counterparties or professional clients and should be made available only to such persons and is exempt from the restriction on financial promotion in s21 of the Financial Services and Markets Act 2000 in reliance on provision in the FPO.

Copyright

This publication or report may not be mechanically duplicated, photocopied or otherwise reproduced, in full or in part, under applicable copyright laws. Any infringement of Pareto Securities Research's copyright can be pursued legally whereby the infringer will be held liable for any and all losses and expenses incurred by the infringement.

Appendix A

Disclosure requirements in accordance with Commission Delegated Regulation (EU) 2016/958 and the FINRA Rule 2241

The below list shows companies where Pareto Securities AS - together with affiliated companies and/or persons – owns a net long position of the shares exceeding 0,5 % of the total issued share capital in any company where a recommendation has been produced or distributed by Pareto Securities AS.

Companies	No. of shares	Holdings in %
Austevoll Seafood	1 076 640	0,53 %
Bonheur	243 488	0,57 %
Pareto Bank	16 185 349	21,08 %
Pexip Holding	770 295	0,74 %
SpareBank 1 Nord-Norge	5 016 421	5,00 %
SpareBank 1 SMN	2 965 805	2,28 %
SpareBank 1 SR-Bank	2 623 544	0,99 %
SpareBank 1 Østfold Akershus	1 234 613	9,97 %
SpareBank 1 Østlandet	7 105 329	6,69 %
Sparebanken Sør	505 000	1,21 %
Sparebanken Vest	9 844 498	8,97 %

Pareto Securities AS may hold financial instruments in companies where a recommendation has been produced or distributed by Pareto Securities AS in connection with rendering investment services, including Market Making.

Please find below an overview of material interests in shares held by employees in Pareto Securities AS, in companies where a recommendation has been produced or distributed by Pareto Securities AS. "By material interest" means holdings exceeding a value of NOK 50 000.

Company	Analyst holdings*	Total holdings
2020 Bulklers		8 500
2G Energy		340
ABB Ltd.		580
ABL Group		37 973
Aker ASA	500	2 241
Aker BP		14 495
Aker Carbon Capture		8 976
AMSC ASA		3 640
Aprila Bank		22 675
Austevoll Seafood		2 923
AutoStore		50 000
B3 Consulting Group		2 096
BB Biotech		460
Baerenberg		98 700
Belships		12 600
Biolvent		15 000
Bonheur		30 618
Bouvet		3 200
BW Energy		50 959
BW LPG		450
BW Offshore		3 000
Cool Company		610
Crayon		18 968
Deep Value Driller		10 650
Dermapham Holding SE		850
DNB		26 402
DNO		82 731
Egetis Therapeutics		6 855
Ekem		249 170
Elmera Group ASA		32 755

Company	Analyst holdings*	Total holdings
Elopak		152 300
Embracer Group		56 520
Encavis AG		630
Equinor		5 114
Flex LNG		250
Frontline		7 410
Gaming Innovation Group		10 010
Ganel Energy		5 700
GFT Technologies		420
Gjensidige Forsikring	519	3 169
Golden Ocean Group		995
Grieg Seafood		11 801
Hafnia Ltd.		106 178
Hennes & Mauritz B		1 085
Himalaya Shipping		6 000
Høegh Autoliners		463
International Petroleum Corp		7 676
International Seaways		192
Kitron		22 708
Komplett ASA		347 114
Kongsberg Gruppen		195
Kontron AG		350
Lea bank		16 355
Lerøy Seafood Group		66 175
Link Mobility Group		115 000
Lundin Mining Corp.		7 652
Magnora ASA		31 170
Morrow Bank		171 200
Mowi		11 376
Multitude		2 443
Mutares SE & Co. KGaA		433
NorAm Drilling		6 883
NORBIT		1 070
Nordic Semiconductor		56 559
Norsk Hydro		79 351
Norske Skog		81 149
Okeanis Eco Tankers		6 372
Orkla		7 086
Otovo ASA		25 400
Panoro Energy		32 733
Pareto Bank		828 865
PetroTal		20 000
Pexip Holding		770 295
Protector Forsikring		9 426
PSI Software		300
Quantafuel		16 665
REC Silicon		21 739
SallMar		224
Sandnes Sparebank		2 500
Schibsted		855
Scorpio Tankers		5 000
Seadrill Ltd		7 555
Securitas AB		656
Solstad Offshore		1 500
SpareBank 1 Nord-Norge	725	10 744
SpareBank 1 SMN		7 443
SpareBank 1 SR-Bank		21 447
SpareBank 1 Østlandet	1 100	1 530
Sparebanken Mere		950
Sparebanken Sør		25 000
Sparebanken Vest		2 241
Sparebanken Øst		4 709
Star Bulk Carriers		2 500
Stolt-Nielsen		2 000
Stora Enso		1 396
Storebrand	100	2 300
Storytel		22 115
Subsea 7		20 975
Telenor		3 563
Telia Company		5 000
TGS		11 300
Thule Group		800
TORM		2 000
Transocean		10 000
Valaris		3 427
Vestas Wind Systems		1 275
Viscom		1 300
Volue		101 415
Vår Energi		294 046
Wallenius Wilhelmsen		3 000
Yara		21 219
Zaptec		33 000

This overview is updated monthly (last updated 17.06.2024).

*Analyst holdings refers to positions held by the Pareto Securities AS analyst covering the company.

Appendix B

Disclosure requirements in accordance with Article 6(1)(c)(iii) of Commission Delegated Regulation (EU) 2016/958

Overview over issuers of financial instruments where Pareto Securities AS have prepared or distributed investment recommendation, where Pareto Securities AS have been lead manager/co-lead manager or have rendered publicly known not immaterial investment banking services over the previous 12 months:

3t Global	Penfield Shipping LLC
Acroud AB	PGS
Advanzia Bank S.A.	PHM Group Holding
Alterra Infrastructure	Point Resources Holding AS
Alva Industrier AS	potLight ASA
AMSC ASA	Prosafe
APK AG	Protector Forsikring
Argeo AS	Proximar Seafood
Austevoll Seafood	Quality Living Residential AS
Ayfie Group AS	Saga Robotics ASA
Beerenberg Services AS	Seacrest Petroleo Bermuda Ltd
Bonheur ASA	SFL Corporation Ltd.
Booster Precision Components GmbH	Shamaram Petroleum
Borr Drilling	Shearwater Geoservices
BP Inv3 Topco Limited (TWMA)	Solstad Offshore
BW Energy	Sparebanken Sar
BW Epic Kosan	SSCP Lager Bidco AB
BW Group Limited	Talos Production Inc.
Caboniline Group Holding	Tomagruppen
Cadeler	Treasure ASA
Capsol Technologies ASA	Varel Energy Solutions
CEMASys AS	Vesterålen Havbruk AS
Clemens Kraft AS	Vow Green Metals
Crayon	Yinson Production Financial Services Pte. Ltd.
DEAG Deutsche Entertainment AG	
Deligmit	
Desert Control AS	
DNO	
DOF	
Dolphin Drilling	
EIK Servering AS	
Energy Drilling Pte. Ltd.	
Exlog	
Floateil	
Fredrikstad Energi AS	
Frey ASA	
GC Rieber Shipping ASA	
Gjensidige Forsikring	
Golden Energy Offshore Services	
Grantvedt	
Hawk Infinity Software	
Hertha BSC GmbH & Co. KGaA	
HMH Holding B.V.	
Huddyt AS	
Hunton Fiber AS	
HydrogenPro	
HÖRMANN Industries GmbH	
Inin Group AS	
Insr ASA	
International Petroleum Corp. ("IPC")	
Jarsteinen AS	
Karlsberg Brauerei GmbH	
Katjes International GmbH&CO	
KIME Akva AS	
Klaveness Combination Carriers	
KMC Properties	
Krow Bidco AS	
Learn'd SE	
LifeFit Group Midco GmbH	
Logistic Contractors AS	
LoneStar Group	
Minerva Topco AS	
Mintra Group	
Morrow Bank	
Mutares SE & Co. KGaA	
NEXT Biometrics Group ASA	
NIP 3 AS	
Nordic Aqua Partners	
Nordic Halibut	
Nordic Unmanned	
Norse Atlantic	
Norsk Renewables AS	
North Investment Group AB (Sono Group)	
OKEA	
One Publicus Midco AB	
Otovo ASA	
Pareto Bank	
Pelagia Holding AS	

This overview is updated monthly (this overview is for the period 01.06.2023 – 31.05.2024).

Appendix C

Disclosure requirements pursuant to the Norwegian Securities Trading Regulation § 3-11 (4)

Distribution of recommendations	
Recommendation	% distribution
Buy	71 %
Hold	28 %
Sell	1 %

Distribution of recommendations (transactions*)	
Recommendation	% distribution
Buy	82 %
Hold	18 %
Sell	0 %

* Companies under coverage with which Pareto Securities Group has on-going or completed public investment banking services in the previous 12 months

This overview is updated monthly (last updated 17.06.2024).

Appendix D

This section applies to research reports prepared by Pareto Securities AB.

Disclosure of positions in financial instruments

The beneficial holding of the Pareto Group is 1 % or more of the total share capital of the following companies included in Pareto Securities AB's research coverage universe: None

The Pareto Group has material holdings of other financial instruments than shares issued by the following companies included in Pareto Securities AB's research coverage universe: None

Disclosure of assignments and mandates

Overview over issuers of financial instruments where Pareto Securities AB has prepared or distributed investment recommendation, where Pareto Securities AB has been lead manager or co-lead manager or has rendered publicly known not immaterial investment banking services over the previous twelve months:

ADDrise Group AB	HANZA AB	Xbrane Biopharma AB
Awardit AB	Hexicon AB	Xspray Pharma AB
B3 Consulting Group	Minesto AB	VEF AB
Bioivca International AB	Nordrest Holding AB	Vicore Pharma Holding AB
Camurus AB	Renewcell AB	YNV Global AB
Gaming Innovation Group	Stille AB	Webrock Ventures AB

Members of the Pareto Group provide market making or other liquidity providing services to the following companies included in Pareto Securities AB's research coverage universe:

Attraction AB	Maximum Entertainment AB	Sedana Medical AB
Implantica AG	Mentice AB	VEF
Lundin Gold	Modelon AB	Webrock Ventures AB

Members of the Pareto Group have entered into agreements concerning the inclusion of the company in question in Pareto Securities AB's research coverage universe with the following companies: None

Member of the Pareto Group is providing Business Management services to the following companies:

Aarhus Rssidentials	Hallsell Property Invest AB	Mälarsen AB
Backaheden Fastighets AB	Korsängen Fastighets AB (publ)	One Publicus Fastighets AB
Bonåsudden Holding AB (publ)	Krona Public Real Estate AB	Origa Care AB (publ)
Borglanda Fastighets AB	Logistri Fastighets AB	Preservium Property AB
Fleming Properties AB		

Members of the Pareto Group have entered into agreements concerning the inclusion of the company in question in Pareto Securities AB's research coverage universe with the following companies: None

This overview is updated monthly (last updated 24.06.2024).

Appendix E

Disclosure requirements in accordance with Article 6(1)(c)(i) of Commission Delegated Regulation (EU) 2016/958

Designated Sponsor

Pareto Securities acts as a designated sponsor for the following companies, including the provision of bid and ask offers. Therefore, we regularly possess shares of the company in our proprietary trading books. Pareto Securities receives a commission from the company for the provision of the designated sponsor services.

ad pepper media International N.V.	Kontron	Pyrum Innovations
Bioteest	Logwin	Redcare Pharmacy N.V.
Corestate Capital Holding S.A.	Manz	ReFuels N.V.
Daldrup & Söhne	MAX Automation SE	Salmones Camanchaca S.A.
DEMIRE	Merkur Privatbank	Seven Principles
DF Deutsche Forfait	Meta Wolf	SMT Scharf
Enapter	MLP SE	Surteco SE
Foris	MPC Container Ships ASA	Szyzgy
Gesco SE	Mutares SE	TTL Beteiligungs- und Grundbesitz
GFT Technologies SE	OVB Holding	Uzin Utz SE
Heidelberg Pharma	ProCredit Holding	VERIANOS SE
INTERSHOP Communications	PWO	Viscom
IUV Traffic	PSI Software SE	WPU - Waste Plastic Upcycling AS

Appendix F

Disclosure requirements in accordance with Article 6(1)(c)(iv) of Commission Delegated Regulation (EU) 2016/958

Sponsored Research

Pareto Securities has entered into an agreement with these companies about the preparation of research reports and – in return – receives compensation.

BB Biotech	Hypoport SE	OVB Holding
Bioteest	INDUS Holding	pferdewetten.de
CLIQ Digital	INTERSHOP Communications	ProCredit Holding
Daldrup & Söhne	Kontron	PWO
Dermapharm Holding SE	Logwin	PSI Software
Enapter	Manz	SMT Scharf
Epigenomics	MAX Automation	Surteco
ExpreS2ion Biotech Holding AB	Merkur Privatbank	Szyzgy
GFT Technologies	MLP SE	Viscom
H2APEX Group	Mutares SE	
Heidelberg Pharma	Mynaric	

This overview is updated monthly (last updated 17.06.2024).